Keyword,Priority
ADC,Medium
AZD9592,Medium
Buparlisib,High
BURAN,High
CDH17,Medium
CEACAM5,Medium
c-MET,Medium
CRC AND BRAF-WT,High
CRC AND CTLA-4,High
CRC AND MSS,High
CRC AND RAS-WT,High
CRC AND refractory,High
CRC AND Vaccines,Medium
EGFR and CRC,High
EGFR Bispecific,High
EGFR-targeted and CRC,High
EpCAM,Medium
Ficerafusp,Medium
Ficlatuzumab,Medium
GUCY2C,High
INBRX-106,Medium
Keynote-689,High
Locally advanced AND HNSCC,High
Petosemtamab,Medium
WRN (werner syndrome helicase),Medium
Zanzalintinib,Medium
